Crescita Therapeutics Inc (CTX) — Capital Reinvestment Ratio

Latest as of December 2025: 1.74x

Crescita Therapeutics Inc (CTX) has a Capital Reinvestment Ratio of 1.74x as of December 2025, meaning it reinvests 2% of its operating cash flow (CA$416.00K) in capital expenditures (CA$724.00K). See CTX net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

1.74x
Capex / Operating Cash Flow

Operating Cash Flow

CA$416.00K
CAD

Capital Expenditures

CA$724.00K
CAD

Data as of

Dec 2025
Most recent filing

Crescita Therapeutics Inc Capital Reinvestment Ratio (2019–2025)

This chart tracks Crescita Therapeutics Inc's Capital Reinvestment Ratio across 5 annual periods. Check Crescita Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Crescita Therapeutics Inc (2019–2025)

Year-by-year Capital Reinvestment Ratio for Crescita Therapeutics Inc from 2019 to 2025. For live market cap and broader valuation context, see Crescita Therapeutics Inc (CTX) market capitalisation.

Year Reinvestment Ratio Operating CF (CAD) Capital Expenditures YoY Change
2025 0.31x CA$1.07 Million CA$333.00K ▼ -28.6%
2024 0.43x CA$2.73 Million CA$1.19 Million ▲ +578.8%
2023 0.06x CA$2.08 Million CA$133.00K ▲ +508.9%
2020 0.01x CA$5.61 Million CA$59.00K ▼ -74.0%
2019 0.04x CA$5.31 Million CA$215.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow